רווח נקי למניה (EPS TTM): Biofrontera Inc (BFRI)

Biofrontera Inc. delegates production to third-party CMOs, focusing on licensing and marketing in the US. Net income per share over 12 months illustrates the profitability trend, where the -0.59 mark serves as a key metric. Revenues are based on the sale of photodynamic therapy systems and Ameluz in medical centers. Low geopolitical pressure and stable imports from Germany provide a neutral backdrop.

Stable exports of dermatological products from Germany to the US provide Biofrontera Inc. (BFRI) with a neutral operational backdrop. This specific annual revenue metric mathematically isolates net profit from the impact of share issuance. This chart allows for the immediate tracking of rising debt service costs amid the Fed's tight monetary policy. It is critical for investors to utilize this indicator as a filter to avoid overpaying for the asset. The final value determines the fundamental attractiveness of the issuer's capital.